Dr. Markus Roggen, president and chief science officer of Vancouver-based Delic Labs, delves into the less favorable side of psychedelic research.
The analytical lab model needs an upgrade to serve the medical cannabis industry, writes QNTM founders Justin Ihnken and Connor Murphy and Agilent's Anthony Macherone.
Analytical Cannabis caught up with Paulson to learn more about his lab's recent study of hemp-derived THC products.
Applicants must propose a study that will focus on either sustainable water and energy use, pest management and fertilizer practices, or overall ecological health.
In a class action lawsuit filed on October 28, seen by Analytical Cannabis, a plaintiff alleges that pre-rolls sold by the companies Greenfield Organix and LPF JV Corporation contain less THC than advertised.
California’s cannabis regulator has tightened some of its rules and loosened others.
Once enacted, the proposal will give any adult in the state, aged 21 and over, the legal right to possess, use, cultivate and share psilocybin, ibogaine, mescaline (not derived from peyote), DMT, and psilocyn without fear of arrest.
Based on these findings, the researchers theorize that more restrictive frameworks for cannabis use may not be effective at preventing use during times of great stress.
The delta-8 market urgently needs more oversight and higher safety standards, according to a new viewpoint letter.